Trevena Inc (TRVN): Maxine Gowen , CEO of Trevena Inc purchased 22,084 shares on May 26, 2016. The Insider buying transaction was reported by the company on May 31, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.16 per share for a total value of $157,274.72 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 11, 2015, David Soergel (Sr. VP,Clinical Dev. & CMO) sold 27,217 shares at $10.55 per share price.
Shares of Trevena Inc (TRVN) ended Friday, May 27, 2016 session in red amid volatile trading. The shares closed down -0.04 points or -0.56% at $7.06 with 4,80,655 shares getting traded. Post opening the session at $7.09, the shares hit an intraday low of $6.98 and an intraday high of $7.22 and the price vacillated in this range throughout the day. The company has a market cap of $368 M and the number of outstanding shares has been calculated to be 5,21,74,299 shares. The 52-week high of Trevena Inc is $13.57 and the 52-week low is $5.06.
Company has been under the radar of several Street Analysts.Trevena Inc is Reiterated by FBR Capital to Outperform and the brokerage firm has raised the Price Target to $ 16 from a previous price target of $13 .The Rating was issued on May 17, 2016.Trevena Inc is Reiterated by Needham to Buy while Lowering the Price Target of the company shares to $ 11 from a previous price target of $14 . The Rating was issued on May 17, 2016.Trevena Inc is Initiated by FBR Capital to Outperform and the brokerage firm has set the Price Target at $16. The Rating was issued on Mar 29, 2016.
Trevena Inc. (Trevena) is a clinical-stage biopharmaceutical company. The Company discovers develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform the Company has identified and advanced three differentiated product candidates: TRV130 a small molecule G protein biased ligand at the mu-opioid receptor to treat patients experiencing moderate to severe acute pain where IV administration is preferred; TRV734 a small molecule G protein biased ligand at the mu-opioid receptor to treat moderate to severe acute and chronic pain and TRV027 a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R) inhibiting G protein signaling and activating b-arrestin signaling. The Company has also identified a new product candidate TRV250 a small molecule G protein biased ligand of the delta-opioid receptor program focused on central nervous system (CNS).